At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,118 enrolled
Drug / intervention
Suzetrigine (SUZ) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
In Brief
A Phase 3 clinical trial evaluating Suzetrigine (SUZ), HB/APAP, and 2 other interventions for Acute Pain. Completed, enrolled 1,118 participants across 12 sites.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartOct 2022
Primary CompletionAug 2023
Study CompletionSep 2023
TodayJul 2026
First PostedSep 28, 2022
Enrollment StartOct 10, 2022
Primary CompletionAug 25, 2023
Study CompletionSep 11, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.8 years ago
Interventions
Suzetrigine (SUZ)drug
Tablets for oral administration.
HB/APAPdrug
Capsules for oral administration.
Placebo (matched to SUZ)drug
Placebo matched to SUZ for oral administration.
Placebo (matched to HB/APAP)drug
Placebo matched to HB/APAP for oral administration.